Deucravacitinib for moderate-to-severe chronic plaque psoriasis

Skin

Blood and Immune System

17 February 2025

Published on 17 Feb 2025
Last Updated on 17 Feb 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended deucravacitinib for inclusion on the MOH List of Subsidised Drugs for treating moderate-to-severe chronic plaque psoriasis. The decision was based on the unfavourable clinical and cost effectiveness of deucravacitinib compared with adalimumab, and the unacceptable price-volume agreement proposed by the company.

Deucravacitinib for moderate-to-severe chronic plaque psoriasis (17 Feb 2025) [PDF, 246 KB]

PES Deucravacitinib for treating moderate-to-severe chronic plaque psoriasis (17 Feb 2025) [PDF, 93 KB]